Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study
Rev. latinoam. enferm. (Online); 25 (), 2017
ABSTRACT Introduction: the use of palivizumab as prophylaxis of the respiratory syncytial virus is not a consensus. In Brazil, it is a public health program, but other countries do not consider it cost-effective. Objective: to identify the rate of hospitalization in Intensive Care Unit for respiratory ...
